IP Library Granted Patent US 7,923,042
Granted Patent B2
US 7,923,042 · App. 11/996,310 · Granted Apr 12, 2011

Medicated gauze

Assignee: Svas Biosana S.R.L.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,923,042
App. No.
11/996,310
Granted
Apr 12, 2011
Kind
B2
Abstract

The present invention relates to a medicated gauze containing as active ingredient, aliantoin, a Centella asiatica extract and, optionally, an Urtica dioica extract.

Claims (12)

1. A composition in the form of an ointment for treating cutaneous lesions comprising a mixture of principles in combination with dermatologically compatible excipients, wherein said active principles consist essentially of a Centella asiatica extract containing at least 4% by weight of total triterpenic fraction, an Urtica dioica extract containing at least 0.3% by weight of total sterols and allantoin, and wherein said extracts are dry extracts and wherein the dry extract of Centella asiatica is from 0.05% to 0.2% by weight, the dry extract of Urtica dioica is from 0.01% to 0.03% by weight and allantoin is from 0.4% to 1.6% by weight.

2. The composition according to claim 1 , wherein said Centella asiatica extract contains 4% by weight of total triterpenic fraction.

3. The composition according to claim 1 , wherein said Urtica dioica extract contains 0.4% by weight of total sterols.

4. The composition according to claim 1 further comprising polyethylene glycols.

5. The composition according to claim 4 , wherein said polyethylene glycols are a mixture of polyethylene glycols having molecular weights of 400, 1500 and 4000 Da.

6. A sterile medicated gauze uniformly impregnated with the composition according to claim 1 .

7. The sterile medicated gauze according to claim 6 , made of hydrophilic cotton.

8. The sterile medicated gauze according to claim 6 , impregnated with an amount of said ointment comprised between 0.03 and 0.05 g per cm 2 .

9. The sterile medicated gauze according to claim 8 wherein said amount of ointment is 0.04 g per cm 2 .

10. A method for topical treatment of cutaneous lesions comprising administering to a patient in need thereof an effective amount of the composition according to claim 1 .

11. The method according to claim 10 , wherein said cutaneous lesions are chronic cutaneous lesions.

12. The method according to claim 10 , wherein said cutaneous lesions are ulcero-dystrophic alterations (varicose ulcers, decubitus sores, torpid sores, fistula tracts, rhagades etc.) burns, lesiions resulting from delayed post-operative cicatrization and abrasions.

Assignments (2)
CHANGE OF NAME Recorded May 21, 2013
From: SVAS BIOSANA S.R.L.
To: SVAS BIOSANA S.P.A.
Reel/Frame 030453/0761 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 26, 2008
From: COZZOLINO, GUGLIELMO
To: SVAS BIOSANA S.R.L.
Reel/Frame 020419/0754 →
Priority Claims (1)
IT MI2005A1396 · Jul 21, 2005 · national
Continuity (1)
Related Publication 20080226700A1 · Sep 18, 2008